Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: Three multiresistant human pathogenic yeasts

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3641-3651

  Cendejas Bueno, E ^a   Kolecka, A ^b   Alastruey Izquierdo, A ^a   Theelen, B ^b   Groenewald, M ^b   Kostrzewa, M ^c   Cuenca Estrella, M ^a   Gomez Lopez A ^a   Boekhout, Teun ^b,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c BRUKER DALTONIK GMBH   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; INTERNAL TRANSCRIBED SPACER; ITRACONAZOLE; MICAFUNGIN; NUCLEAR RNA; POSACONAZOLE; PYRROLE DERIVATIVE; RIBOSOME RNA; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CANDIDA AURIS; CANDIDA DUOBUSHAEMULONII; CANDIDA HAEMULONII; CANDIDA PSEUDOHAEMULONII; CANDIDA VULNERA; CLASSIFICATION; CONTROLLED STUDY; CROSS RESISTANCE; FUNGAL GENE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE SEQUENCE; INTERMETHOD COMPARISON; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NEW SPECIES; NONHUMAN; NUCLEOTIDE SEQUENCE; OPERON; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; TAXONOMY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CLUSTER ANALYSIS; DNA, FUNGAL; DNA, RIBOSOMAL SPACER; DRUG RESISTANCE, MULTIPLE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

EID: 84867536494     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02248-12     Document Type: Article

References (41)

1. Alcoba-Flórez J, et al. 2005. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J. Clin. Microbiol. 43:4107-4111.
2. Bolano A, et al. 2001. Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res. 1:221-224. (Pubitemid 34442271)
3. Borst A, et al. 2003. Use of amplified fragment length polymorphism analysis to identify medically important Candida spp., including C. dubliniensis. J. Clin. Microbiol. 41:1357-1362. (Pubitemid 36428073)
4. Cendejas-Bueno E, Gomez-Lopez A, Mellado E, Rodríguez-Tudela JL, Cuenca-Estrella M. 2010. Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. J. Clin. Microbiol. 48:1895-1899.
5. Correia A, Sampaio P, James S, Pais C. 2006. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int. J. Syst. Evol. Microbiol. 56:313-317. (Pubitemid 43125932)
6. Crouzet J, Sotto A, Picard E, Lachaud L, Bourgeois N. 2011. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin. Microbiol. Infect. 17:1068-1070.
7. Cuenca-Estrella M, et al. 2008. Update on the epidemiology and diagnosis of invasive fungal infection. Int. J. Antimicrob. Agents 32(Suppl 2):S143-S147.
8. Cuenca-Estrella M, et al. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921. (Pubitemid 43327795)
9. Cuenca-Estrella M, et al. 2003. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9:467-474. (Pubitemid 36833790)
10. Cuenca-Estrella M, et al. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. 55:194-199. (Pubitemid 40331145)
11. de Hoog GS, Gerrits van den Ende AH. 1998. Molecular diagnostics of clinical strains of filamentous basidiomycetes. Mycoses 41:183-189.
12. Fleischhacker M, Radecke C, Schulz B, Ruhnke M. 2008. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis. 27:127-131.
13. Gargeya IB, Pruitt WR, Meyer SA, Ahearn DG. 1991. Candida haemulonii from clinical specimens in the USA. J. Med. Vet. Mycol. 29:335-338.
14. Holá V, Ruzicka F, Horka M. 2010. Microbial diversity in biofilm infections of the urinary tract with the use of sonication techniques. FEMS Immunol. Med. Microbiol. 59:525-528.
15. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP. 2003. Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J. Clin. Microbiol. 41:2961-2967. (Pubitemid 36842285)
16. Khan ZU, et al. 2007. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole. J. Clin. Microbiol. 45:2025-2027. (Pubitemid 46933952)
17. Kim MN, et al. 2009. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin. Infect. Dis. 48:e57-e61.
18. Kim S, et al. 2011. Catheter-related candidemia caused by Candida haemulonii in a patient in long-term hospital care. J. Korean Med. Sci. 26:297-300.
19. Kolecka A, Hernandez-Barbado R, Rupp S, Bujdakova H. 2011. Biofilm formation and adhesive/invasive properties of Candida dubliniensis in comparison with Candida albicans. Centr. Eur. J. Biol. 6:893-901.
20. Kurtzman CP, Fell JW, Boekhout T. 2011. The yeasts: a taxonomic study, 5th edition. Elsevier, Amsterdam, the Netherlands.
21. Kurtzman CP, Robnett CJ. 1997. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene. J. Clin. Microbiol. 35:1216-1223. (Pubitemid 27175254)
22. Lavarde V, Daniel F, Saez H, Arnold M, Faguer B. 1984. Peritonite mycosique a Torulopsis haemulonii. Bull. Soc. Fr. Mycol. Med. 13:173-176.
23. Lee WG, et al. 2011. First three reported cases of nosocomial fungemia caused by Candida auris. J. Clin. Microbiol. 49:3139-3142.
24. Lehmann PF, Wu LC, Pruitt WR, Meyer SA, Ahearn DG. 1993. Unrelatedness of groups of yeasts within the Candida haemulonii complex. J. Clin. Microbiol. 31:1683-1687. (Pubitemid 23182558)
25. Li X, Yan Z, Xu J. 2003. Quantitative variation of biofilms among strains in natural populations of Candida albicans. Microbiology 149:353-362. (Pubitemid 36285192)
26. Liu YJ, Whelen S, Hall BD. 1999. Phylogenetic relationships among ascomycetes: evidence from an RNA polymerase II subunit. Mol. Biol. Evol. 16:1799-1808.
27. Marklein G, et al. 2009. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J. Clin. Microbiol. 47:2912-2917.
28. Oh BJ, et al. 2011. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med. Mycol. 49:98-102.
29. Pinto A, et al. 2011. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 6:e25712. doi:10.1371/journal.pone.0025712.
30. Rodero L, et al. 2002. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J. Clin. Microbiol. 40:2266-2269. (Pubitemid 34596426)
31. Rodríguez-Tudela JL, et al. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604. (Pubitemid 47519349)
32. Rodriguez-Tudela JL, et al. 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
33. Rodriguez-Tudela JL, et al. 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
34. Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. 2010. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Int. J. Antimicrob. Agents 35:85-88.
35. Satoh K, et al. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 53:41-44.
36. Schoch CL, et al. 2012. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. Proc. Natl. Acad. Sci. U. S. A. 109:6241-6246.
37. Shin JH, et al. 2002. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J. Clin. Microbiol. 40:1244-1248. (Pubitemid 34279883)
38. Sugita T, Takashima M, Poonwan N, Mekha N. 2006. Candida pseudohaemulonii sp. nov., an amphotericin B- and azole-resistant yeast species, isolated from the blood of a patient from Thailand. Microbiol. Immunol. 50:469-473. (Pubitemid 43927236)
39. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292. (Pubitemid 40096313)
40. van Uden N, Kolipinsky MC. 1962. Torulopsis haemulonii nov. spec., a yeast from the Atlantic Ocean. Antonie Van Leeuwenhoek 28:78-80.
41. Yarrow D, Meyer SA. 1978. Proposal for amendment of the diagnosis of the genus Candida Berkhout nom. cons. Int. J. Syst. Bacteriol. 28:611-615. (Pubitemid 9054795)